Skip to main content

Vivian Wu

Head of Investor Relations

Nektar Therapeutics (NKTR)

Equibles does not estimate personal net worth.

Get an email with a short summary when Nektar Therapeutics publishes a filing, an earnings call transcript or a press release.

Get NKTR alerts

About Vivian Wu

Vivian Wu is recorded as Head of Investor Relations at Nektar Therapeutics (NKTR). Vivian Wu has spoken on 6 earnings calls and 2 other investor events across 1 company, most recently for Nektar Therapeutics on November 12, 2026. Nektar Therapeutics is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Nektar Therapeutics includes Howard Robin (CEO), Jillian Thomsen (CFO and Chief Accounting Officer), Linda Rubinstein (CFO) and 2 others.

Vivian Wu on recent calls

“On today's call, you will hear from Howard Robin, our President and Chief Executive Officer, Dr. Mary Tagliaferri, our Chief Medical Officer, Dr. Jonathan Zaleski, our Chief Research and Development Officer, and Linda Rubenstein, our Chief Financial Officer.”
Head of Investor Relations, Nektar Therapeutics Q3 2026 Financial Results ·
“Thank you for joining us today to discuss new data being presented at the EADV 2026 Congress.”
Head of Investor Relations, Analyst and Investor Event at EADV ·
“On today's call, you will hear from Howard Robin, our President and Chief Executive Officer, Dr. Jonathan Zalewski, our Chief Research and Development Officer, and Sandra Gardner, our Chief Financial Officer.”
Head of Investor Relations, Nektar Therapeutics Q1 FY2026 Earnings Call ·
“Today, you will hear from Howard Robin, our President and Chief Executive Officer, Dr. John Zinczewski, our Chief Research and Development Officer, and Dr. Mary Tagliaferri, our Chief Medical Officer.”
Head of Investor Relations, Analyst and Investor Event with Alopecia Areata Experts ·
“Today, you will hear from Howard W. Robin, our President and Chief Executive Officer; Dr. Jonathan Zalevsky, our Chief Research and Development Officer; and Sandra A. Gardiner, our Chief Financial Officer.”
Head of Investor Relations, Nektar Therapeutics Q4 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Nektar Therapeutics

Recent activity